Physician profile
Drew Michael Thodeson
NPI 1033347521
$1,735.80
in general payments reported to CMS, 2019-2025
15 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $25.67 · 2021: $178 · 2022: $34.23 · 2023: $935 · 2024: $427 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dixi Medical USA Corp | $728.76 | 2023 | |
| Sk Life Science, INC. | $242.08 | 2024-2025 | |
| Biomarin Pharmaceutical INC. | $160.58 | 2021-2024 | Palynziq |
| Jazz Pharmaceuticals INC. | $137.45 | 2023 | |
| Phadia US INC. | $90.60 | 2021 | |
| Neurelis, INC. | $72.05 | 2024-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $60.04 | 2023-2024 | Koselugo |
| Livanova USA, INC. | $56.33 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $51.10 | 2022-2024 | Briviact |
| Biogen, INC. | $37.38 | 2021-2023 | Spinraza |
| Ptc Therapeutics, INC. | $25.67 | 2020 | |
| Greenwich Biosciences, INC. | $25.00 | 2021 | |
| Abbvie INC. | $19.86 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.30 | 2023 | Eprontia |
| Zogenix INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Thodeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.